Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?

References

• Al Ameri MN, Makramalla E, Albur U, et al. Prevalence of polypharmacy in the elderly: implications of age, gender, comorbidities and drug interactions. SOJ Pharm Pharm Sci. 2014;1:1–7.
   Google Scholar
• Kim H-A, Shin J-Y, Kim M-H, et al. Prevalence and predictors of polypharmacy among Korean elderly. PLoS One. 2014;9:e98043.
   PubMed Web of Science ®Google Scholar
• Maheshkumar VP, Dhanapal CK. Prevalence of polypharmacy in geriatric patients in rural teaching hospital. Am J Phytomed Clin Ther. 2014;2:413–419.
   Google Scholar
• Le Cossec C, Sermet C. Measuring polypharmacy in the elderly: impact of the method on prevalence and therapeutic classes. Questions d’économie de la santé n°213 - October 2015.
   Google Scholar
• Nobili A, Franchi C, Pasina L, et al. Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-elderly project. Pharmacoepidemiol Drug Saf. 2011;20:488–496.
   PubMed Web of Science ®Google Scholar
• Silveira EA, Dalastra L, Pagotto V. Polypharmacy, chronic diseases and nutritional markers in community-dwelling older. Rev Bras Epidemiol. 2014;17:818–829.
   PubMedGoogle Scholar
• Kwan D, Farrell B. Polypharmacy: optimizing medication use in elderly patients. CGS J CME. 2014;4:21–27.
   Google Scholar
• Geda YE, Schneider LS, Gitlin LN, et al.; Neuropsychiatric Syndromes Professional Interest Area of ISTAART. Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9:602–608.
   PubMed Web of Science ®Google Scholar
• Seitz D, Purandare N, Conn D. Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review. Int Psychogeriatr. 2010;22:1025–1039.
   PubMed Web of Science ®Google Scholar
• Panza F, Frisardi V, Seripa D, et al. Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer’s disease. Ageing Res Rev. 2012;11:87–103.
   PubMed Web of Science ®Google Scholar
• Ruscin MJ. Drug therapy in the elderly. In: Porter RS, Kaplan JL, editors. The Merck manual. Kenilworth (NJ): Merck, Sharp & Dohme Corp.; 2011. p. 3090–3098.
   Google Scholar
• Cooper JA, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ Open. 2015;5:e009235.
   PubMed Web of Science ®Google Scholar
• Rohrer JE, Garrison G, Oberhelman SA, et al. Epidemiology of polypharmacy among family medicine patients at hospital discharge. J Prim Care Community Health. 2013;4:101–105.
   PubMedGoogle Scholar
• Löffler C, Drewelow E, Paschka SD, et al. Optimizing polypharmacy among elderly hospital patients with chronic diseases - study protocol of the cluster randomized controlled POLITE-RCT trial. Implement Sci. 2014;9:151.
   PubMed Web of Science ®Google Scholar
• Currin JB, Hayslip B Jr, Schneider LJ, et al. Cohort differences in attitudes toward mental health services among older persons. Psychotherapy. 1998;35(4):506–518.
   Web of Science ®Google Scholar
• Maust DT, Gerlach LB, Gibson A, et al. Trends in central nervous system-active polypharmacy among older adults seen in outpatient care in the United States. JAMA Intern Med. 2017;177:583–585.
   PubMed Web of Science ®Google Scholar
• Prudent M, Dramé M, Jolly D, et al. Potentially inappropriate use of psychotropic medications in hospitalized elderly patients in France: cross-sectional analysis of the prospective, multicentre SAFEs cohort. Drugs Aging. 2008;25:933–946.
   PubMed Web of Science ®Google Scholar
• Shah SM, Carey IM, Harris T, et al. Quality of prescribing in care homes and the community in England and Wales. Br J Gen Pract. 2012;62:329–336.
   PubMed Web of Science ®Google Scholar
• Bishop TF, Seirup JK, Pincus HA, et al. Population of US practicing psychiatrists declined, 2003-13, which may help explain poor access to mental health care. Health Aff (Millwood). 2016;35(7):1271–1277.
   PubMed Web of Science ®Google Scholar
• Vivas-Consuelo D, Usó-Talamantes R, Trillo-Mata JL, et al. Methods to control the pharmaceutical cost impact of chronic conditions in the elderly. Expert Rev Pharmacoecon Outcomes Res. 2015;15:425–437.
   PubMed Web of Science ®Google Scholar
• Brixner D, Biltaji E, Bress A, et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2016;19:213–228.
   PubMed Web of Science ®Google Scholar
• Malet-Larrea A, Goyenechea E, Gastelurrutia MA, et al. Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients. Eur J Health Econ. 2016. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Köberlein J, Gottschall M, Czarnecki K, et al. General practitioners’ views on polypharmacy and its consequences for patient health care. BMC Fam Pract. 2013;14:119.
   PubMed Web of Science ®Google Scholar
• Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65.
   PubMed Web of Science ®Google Scholar
• Sehgal V, Bajwa SJS, Sehgal R, et al. Polypharmacy and potentially inappropriate medication use as the precipitating factor in readmissions to the hospital. J Family Med Prim Care. 2013;2:194–199.
   PubMedGoogle Scholar
• Ferner RE. Adverse drug reactions. Clin Pharmacol. 2016;44:416–421.
   Google Scholar
• Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13:74.
   PubMed Web of Science ®Google Scholar
• Raschi E, Piccinni C, Signoretta V, et al. Clinically important drug-drug interactions in poly-treated elderly outpatients: a campaign to improve appropriateness in general practice. Br J Clin Pharmacol. 2015;80:1411–1420.
   PubMed Web of Science ®Google Scholar
• Wallace J, Paauw DS. Appropriate prescribing and important drug interactions in older adults. Med Clin North Am. 2015;99:295–310.
   PubMed Web of Science ®Google Scholar
• Gujjarlamudi HB. Polytherapy and drug interactions in elderly. J Midlife Health. 2016;7:105–107.
   PubMedGoogle Scholar
• Marcum ZA, Pugh MJV, Amuan ME, et al. Prevalence of potentially preventable unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans. J Gerontol A Biol Sci Med Sci. 2012;67:867–874.
   PubMed Web of Science ®Google Scholar
• Patel RS, Marcum ZA, Peron EP, et al. Prevalence of and factors associated with therapeutic failure-related hospitalizations in the elderly. Consult Pharm. 2014;29:376–386.
   PubMedGoogle Scholar
• Lewis PR, Karpa KD, Felix TM. Adverse effects of common drugs: adults. FP Essent. 2015;436:23–30.
   PubMedGoogle Scholar
• Davies EA, O’Mahony MS. Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol. 2015;80:796–807.
   PubMed Web of Science ®Google Scholar
• Carnovale C, Gentili M, Fortino I, et al. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme. Expert Opin Drug Saf. 2016;15:131–139.
   PubMed Web of Science ®Google Scholar
• Laatikainen O, Sneck S, Bloigu R, et al. Hospitalizations due to adverse drug events in the elderly - a retrospective register study. Front Pharmacol. 2016;7:358.
   PubMed Web of Science ®Google Scholar
• Shehab N, Lovegrove MC, Geller AI, et al. US emergency department visits for outpatient adverse drug events, 2013-2014. JAMA. 2016;316:2115–2125.
   PubMed Web of Science ®Google Scholar
• AHRQ - Agency for Healthcare Research and Quality, Advancing Excellence in Health Care. Reducing and preventing adverse drug events to decrease hospital costs. Research in action, Issue 1. [ cited 2017 Aug. 24]. Available from: http://archive.ahrq.gov/research/findings/factsheets/errors-safety/aderia/ade.html
   Google Scholar
• Schatz SN, Weber RJ. Adverse drug reactions. ACCP (American College of Clinical Pharmacy). CNS/Pharmacy Practice, PSAP; 2015 cited 2017 Aug. 24. Available from: https://www.accp.com/docs/bookstore/psap/2015B2.SampleChapter.pdf
   Google Scholar
• Tan Y, Hu Y, Liu X, et al. Improving drug safety: from adverse drug reaction knowledge discovery to clinical implementation. Methods. 2016;110:14–25.
   PubMed Web of Science ®Google Scholar
• Seripa D, Panza F, Daragjati J, et al. Measuring pharmacogenetics in special groups: geriatrics. Expert Opin Drug Metab Toxicol. 2015;11:1073–1088.
   PubMed Web of Science ®Google Scholar
• Davidoff AJ, Miller GE, Sarpong EM, et al. Prevalence of potentially inappropriate medication use in older adults using the 2012 Beers Criteria. J Am Geriatr Soc. 2015;63:486–500.
   PubMed Web of Science ®Google Scholar
• Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6:287–293.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Klein K, Thomas M, et al. Genetics, epigenetics, and regulation of drug-metabolizing cytochrome P450 enzymes. Clin Pharmacol Ther. 2014;95:258–261.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Nebert DW. Evolution of the P450 gene superfamily: animal–plant ‘warfare,’ molecular drive and human genetic differences in drug oxidation. Trends Genet. 1990;6:182–186.
   PubMed Web of Science ®Google Scholar
• Tracy TS, Chaudhry AS, Prasad B, et al. Interindividual variability in cytochrome P450-mediated drug metabolism. Drug Metab Dispos. 2016;44:343–351.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999;20:342–349.
   PubMed Web of Science ®Google Scholar
• The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Allele nomenclature for cytochrome P450 enzymes. [ cited 2017 Aug. 24]. Available from: http://www.cypalleles.ki.se/
   Google Scholar
• Daly AK, Cholerton S, Gregory W, et al. Metabolic polymorphisms. Pharmacol Ther. 1993;57:129–160.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Turpeinen M, Klein K, et al. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008 Nov.;392(6):1093–1108.
   PubMed Web of Science ®Google Scholar
• LLerena A, Dorado P, Peñas-LLedó EM. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics. 2009;10:17–28.
   PubMed Web of Science ®Google Scholar
• De Leon J, Arranz MJ, Ruaño G. Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med. 2008;28:599–617.
   PubMed Web of Science ®Google Scholar
• Peñas-Lledó EM, Llerena A. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials. Br J Clin Pharmacol. 2014;77:673–683.
   PubMed Web of Science ®Google Scholar
• Eleftheriou BE, ed. Psychopharmacogenetics. New York (NY): Plenum Press; 1975.
   Google Scholar
• Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology - with emphasis on cytochrome p450. Toxicol Sci. 2011;120:1–13.
   PubMed Web of Science ®Google Scholar
• Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002;34:83–448.
   PubMed Web of Science ®Google Scholar
• Fick DM, Semla TP, Beizer J, et al. American Geriatrics Society 2015 Updated Beers Criteria for potentially inappropriate medication use in older adults. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. J Am Geriatr Soc. 2015;63:2227–2246.
   PubMed Web of Science ®Google Scholar
• Ruggiero C, Dell’Aquila G, Gasperini B, et al. Potentially inappropriate drug prescriptions and risk of hospitalization among older, Italian, nursing home residents: the ULISSE project. Drugs Aging. 2010;27:747–758.
   PubMed Web of Science ®Google Scholar
• Ćurković M, Dodig-Ćurković K, Erić AP, et al. Psychotropic medications in older adults: a review. Psychiatr Danub. 2016;28:13–24.
   PubMed Web of Science ®Google Scholar
• Gareri P, Segura-García C, Manfredi VG, et al. Use of atypical antipsychotics in the elderly: a clinical review. Clin Interv Aging. 2014;9:1363–1373.
   PubMed Web of Science ®Google Scholar
• Brøsen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Thérapie. 2004;59:5–12.
   PubMed Web of Science ®Google Scholar
• Bertilsson L. Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clin Pharmacol Ther. 2007;82:606–609.
   PubMed Web of Science ®Google Scholar
• Nielsen KK, Brøsen K, Hansen MG, et al. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther. 1994;55:518–527.
   PubMed Web of Science ®Google Scholar
• Rudberg I, Mohebi B, Hermann M, et al. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2008;83:322–327.
   PubMed Web of Science ®Google Scholar
• Steimer W, Zopf K, Von AS, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem. 2005;51:376–385.
   PubMed Web of Science ®Google Scholar
• Liu Y-T, Hao H-P, Liu C-X, et al. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev. 2007;39:699–721.
   PubMed Web of Science ®Google Scholar
• Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc. 2003;51:671–677.
   PubMed Web of Science ®Google Scholar
• Unützer J. Clinical practice. Late-life depression. New Engl J Med. 2007;357:2269–2276.
   PubMed Web of Science ®Google Scholar
• NIH Consensus Conference. Diagnosis and treatment of depression in late life. JAMA. 1992;268:1018–1024.
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease. Expert Opin Pharmacother. 2015;16:2581–2588.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Brosen K, Dahl M, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104:173–192.
   PubMed Web of Science ®Google Scholar
• De Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47:75–85.
   PubMed Web of Science ®Google Scholar
• Serretti A, Calati R, Massat I, et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol. 2009;24:250–256.
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Eap CB, Oneda B, et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit. 2008;30:474–482.
   PubMed Web of Science ®Google Scholar
• Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One. 2008;3:e1872.
   PubMed Web of Science ®Google Scholar
• Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007;9:819–825.
   PubMed Web of Science ®Google Scholar
• Lessard E, Yessine MA, Hamelin BA, et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999;9:435–443.
   PubMedGoogle Scholar
• Chaudhry M, Alessandrini M, Rademan J, et al. Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study. Pharmacogenomics. 2017 Apr.;18(5):433–443.
   PubMed Web of Science ®Google Scholar
• Berm EJ, Hak E, Postma M, et al. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial). Trials. 2015;16:37.
   PubMed Web of Science ®Google Scholar
• Waade RB, Hermann M, Moe HL, et al. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur J Clin Pharmacol. 2014;70:933–940.
   PubMed Web of Science ®Google Scholar
• Dolder C, Nelson M, Stump A. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. Drugs Aging. 2010;27:625–640.
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Dahl M-L, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet. 1993;341:63.
   PubMed Web of Science ®Google Scholar
• Stingl JC, Viviani R. CYP2D6 in the brain: impact on suicidality. Clin Pharmacol Ther. 2011;89:352–353.
   PubMed Web of Science ®Google Scholar
• Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther. 2010;88:354–359.
   PubMed Web of Science ®Google Scholar
• Grasmäder K, Verwohlt PL, Kühn K-U, et al. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol. 2004;60:473–480.
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Streim J, Carpenter D, et al.; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65 Suppl 2:5–99.
   PubMed Web of Science ®Google Scholar
• Nishtala PS, McLachlan AJ, Bell JS, et al. Determinants of antipsychotic medication use among older people living in aged care homes in Australia. Int J Geriatr Psychiatry. 2010;25:449–457.
   PubMed Web of Science ®Google Scholar
• Research Center for Drug Evaluation and Public Health Advisories (Drugs). Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. [ cited 2017 Aug. 24]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety/InformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm
   Google Scholar
• Commissioner of the Safety Alerts for Human Medical Products. Antipsychotics, conventional and atypical. [ cited 2017 Aug. 24]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110212.htm
   Google Scholar
• Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359–1369.
   PubMed Web of Science ®Google Scholar
• Graff-Guerrero A, Rajji TK, Mulsant BH, et al. Evaluation of antipsychotic dose reduction in late-life schizophrenia: a prospective dopamine D2/3 receptor occupancy study. JAMA Psychiatry. 2015;72:927–934.
   PubMed Web of Science ®Google Scholar
• Dahl M-L. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet. 2002;41:453–470.
   PubMed Web of Science ®Google Scholar
• Brockmöller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002;72:438–452.
   PubMed Web of Science ®Google Scholar
• Yoshii K, Kobayashi K, Tsumuji M, et al. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci. 2000;67:175–184.
   PubMed Web of Science ®Google Scholar
• Mulsant BH, Foglia JP, Sweet RA, et al. The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. J Clin Psychopharmacol. 1997;17:318–321.
   PubMed Web of Science ®Google Scholar
• Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999;27:1078–1084.
   PubMed Web of Science ®Google Scholar
• De Leon J, Susce MT, Pan R-M, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66:15–27.
   PubMed Web of Science ®Google Scholar
• Tamminga WJ, Wemer J, Oosterhuis B, et al. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. Eur J Clin Pharmacol. 2003;59:57–64.
   PubMed Web of Science ®Google Scholar
• Hollingworth SA, Siskind DJ. Anxiolytic, hypnotic and sedative medication use in Australia. Pharmacoepidemiol Drug Saf. 2010;19:280–288.
   PubMed Web of Science ®Google Scholar
• Bourgeois J, Elseviers MM, Azermai M, et al. Benzodiazepine use in Belgian nursing homes: a closer look into indications and dosages. Eur J Clin Pharmacol. 2012;68:833–844.
   PubMed Web of Science ®Google Scholar
• Billioti De Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ. 2014;349:g5205.
   PubMed Web of Science ®Google Scholar
• Tannenbaum C, Paquette A, Hilmer S, et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging. 2012;29:639–658.
   PubMed Web of Science ®Google Scholar
• Zint K, Haefeli WE, Glynn RJ, et al. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf. 2010;19:1248–1255.
   PubMed Web of Science ®Google Scholar
• Dassanayake T, Michie P, Carter G, et al. Effects of benzodiazepines, anti-depressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf. 2011;34:125–156.
   PubMed Web of Science ®Google Scholar
• Hampton LM, Daubresse M, Chang H-Y, et al. Emergency department visits by adults for psychiatric medication adverse events. JAMA Psychiatry. 2014;71:1006–1014.
   PubMed Web of Science ®Google Scholar
• Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;348:g1996.
   PubMed Web of Science ®Google Scholar
• Ham AC, Ziere G, Broer L, et al. CYP2C9 genotypes modify benzodiazepine-related fall risk: original results from three studies with meta-analysis. J Am Med Dir Assoc. 2017;18:88.e1–88.e15.
   PubMed Web of Science ®Google Scholar
• Zhou S-F, Zhou Z-W, Yang L-P, et al. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16:3480–3675.
   PubMed Web of Science ®Google Scholar
• Schroeck JL, Ford J, Conway EL, et al. Review of safety and efficacy of sleep medicines in older adults. Clin Ther. 2016;38:2340–2372.
   PubMed Web of Science ®Google Scholar
• Mendiola-Precoma J, Berumen LC, Padilla K, et al. Therapies for prevention and treatment of Alzheimer’s disease. Biomed Res Int. 2016;2016:1–17.
   Web of Science ®Google Scholar
• Campbell N, Ayub A, Boustani MA, et al. Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: a meta-analysis. Clin Interv Aging. 2008;3:719–728.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 2001;11:573–585.
   PubMedGoogle Scholar
• Pilotto A, Franceschi M, D’Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology. 2009;73(10):761–767.
   PubMed Web of Science ®Google Scholar
• Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients. Eur J Clin Pharmacol. 2006;62(9):721–726.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Llovo R, Fraile C, et al. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer’s disease pharmacogenetics. Curr Alzheimer Res. 2007;4(4):479–500.
   PubMed Web of Science ®Google Scholar
• Seripa D, Bizzarro A, Pilotto A, et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer’s disease. Pharmacogenet Genomics. 2011;21:225–230.
   PubMed Web of Science ®Google Scholar
• Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2013;52:225–241.
   PubMed Web of Science ®Google Scholar
• Campbell NL, Skaar TC, Perkins AJ, et al. Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy. Clin Interv Aging. 2015;10:269–275.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Martínez R, Fernández-Novoa L, et al. Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics. Int J Alzheimers Dis. 2012;2012:518901.
   PubMedGoogle Scholar
• Samer CF, Daali Y, Wagner M, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol. 2010;160:919–930.
   PubMed Web of Science ®Google Scholar
• Rollason V, Samer C, Piguet V, et al. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics. 2008;9:905–933.
   PubMed Web of Science ®Google Scholar
• Dechanont S, Maphanta S, Butthum B, et al. Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23:489–497.
   PubMed Web of Science ®Google Scholar
• Gallagher P, Barry P, O’Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32:113–121.
   PubMed Web of Science ®Google Scholar
• Imai T, Hayakawa M, Ohe K. Development of description framework of pharmacodynamics ontology and its application to possible drug-drug interaction reasoning. Stud Health Technol Inform. 2013;192:567–571.
   PubMedGoogle Scholar
• Paulzen M, Haen E, Hiemke C, et al. Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. Br J Clin Pharmacol. 2017;83:1668–1675.
   PubMed Web of Science ®Google Scholar
• Spina E, De Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100:4–22.
   PubMed Web of Science ®Google Scholar
• Bahar MA, Hak E, Bos JHJ, et al. The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly. Pharmacoepidemiol Drug Saf. 2017;26:752–765.
   PubMed Web of Science ®Google Scholar
• Wenzel-Seifert K, Brandl R, Hiemke C, et al. Influence of concomitant medications on the total clearance and the risk for supra-therapeutic plasma concentrations of citalopram. A population-based cohort study. Pharmacopsychiatry. 2014;47:239–244.
   PubMed Web of Science ®Google Scholar
• Letsas K, Sideris A, Kounas SP, et al. Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol. 2006;109:273–274.
   PubMed Web of Science ®Google Scholar
• Ginanneschi F, Volpi N, Giannini F, et al. Rhabdomyolysis in an elderly multitreated patient: multiple drug interactions after statin withdrawal. J Neurol Sci. 2014;336:284–287.
   PubMed Web of Science ®Google Scholar
• Liu H-C, Lin S-K, Sung S-M. Extrapyramidal side-effect due to drug combination of risperidone and donepezil. Psychiatry Clin Neurosci. 2002;56:479.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Xie C, Pesco-Koplowitz L, et al. Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil. J Clin Pharmacol. 2003;43:180–186.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487–491.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Martinez-Bouza R, Carril JC, et al. Genomics and pharmacogenomics of brain disorders. Curr Pharm Biotechnol. 2012;13:674–725.
   PubMed Web of Science ®Google Scholar
• Agrawal AK, Shapiro BH. Latent overexpression of hepatic CYP2C7 in adult male and female rats neonatally exposed to phenobarbital: a developmental profile of gender-dependent P450s. J Pharmacol Exp Ther. 2000;293:1027–1033.
   PubMed Web of Science ®Google Scholar
• Peng L, Yoo B, Gunewardena SS, et al. RNA sequencing reveals dynamic changes of mRNA abundance of cytochromes P450 and their alternative transcripts during mouse liver development. Drug Metab Dispos. 2012;40:1198–1209.
   PubMed Web of Science ®Google Scholar
• Reddington JP, Pennings S, Meehan RR. Non-canonical functions of the DNA methylome in gene regulation. Biochem J. 2013;451:13–23.
   PubMed Web of Science ®Google Scholar
• Naselli F, Catanzaro I, Bellavia D, et al. Role and importance of polymorphisms with respect to DNA methylation for the expression of CYP2E1 enzyme. Gene. 2014;536:29–39.
   PubMed Web of Science ®Google Scholar
• MacDonald JL, Roskams AJ. Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation. Prog Neurobiol. 2009;88:170–183.
   PubMed Web of Science ®Google Scholar
• Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2015;313:2119–2120.
   PubMed Web of Science ®Google Scholar
• Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–795.
   PubMed Web of Science ®Google Scholar
• Finkelstein J, Friedman C, Hripcsak G, et al. Potential utility of precision medicine for older adults with polypharmacy: a case series study. Pharmgenomics Pers Med. 2016;9:31–45.
   PubMed Web of Science ®Google Scholar
• Lozupone M, Panza F, Stella E, et al. Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come? Expert Opin Drug Metab Toxicol. 2017;13:259–277.
   PubMed Web of Science ®Google Scholar
• Samer CF, Lorenzini KI, Rollason V, et al. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013;17:165–184.
   PubMed Web of Science ®Google Scholar
• Preissner SC, Hoffmann MF, Preissner R, et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One. 2013;8:e82562.
   PubMed Web of Science ®Google Scholar
• Chaudhry SR, Muhammad S, Eidens M, et al. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms. Curr Drug Metab. 2014;15:711–718.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141.
   PubMed Web of Science ®Google Scholar
• Isvoran A, Louet M, Vladoiu DL, et al. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discov Today. 2017;22:366–376.
   PubMed Web of Science ®Google Scholar
• Sugarman EA, Cullors A, Centeno J, et al. Contribution of pharmacogenetic testing to modeled medication change recommendations in a long-term care population with polypharmacy. Drugs Aging. 2016;33:929–936.
   PubMed Web of Science ®Google Scholar
• Finkelstein J, Friedman C, Hripcsak G, et al. Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study. Pharmgenomics Pers Med. 2016;9:107–116.
   PubMed Web of Science ®Google Scholar
• Seripa D, Paroni G, Urbano M, et al. Pharmacogenetics in older people: what we know and what we need to know. J Nephrol. 2012;25 Suppl 19:S38–S47.
   PubMed Web of Science ®Google Scholar
• Alomar MJ. Factors affecting the development of adverse drug reactions (review article). Saudi Pharm J. 2014;22:83–94.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, et al.; International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215–236.
   PubMed Web of Science ®Google Scholar
• Iurescia S, Seripa D, Rinaldi M. Role of the 5-HTTLPR and SNP promoter polymorphisms on serotonin transporter gene expression: a closer look at genetic architecture and in vitro functional studies of common and uncommon allelic variants. Mol Neurobiol. 2016;53:5510–5526.
   PubMed Web of Science ®Google Scholar
• Murphy DL, Maile MS, Vogt NM. 5HTTLPR: white knight or dark blight? ACS Chem Neurosci. 2013;4:13–15.
   PubMed Web of Science ®Google Scholar
• Iurescia S, Seripa D, Rinaldi M. Looking beyond the 5-HTTLPR polymorphism: genetic and epigenetic layers of regulation affecting the serotonin transporter gene expression. Mol Neurobiol. 2016. Epub ahead of print. DOI:10.1007/s12035-016-0304-6
   Google Scholar
• Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of serotonin transporter gene polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12:247–257.
   PubMed Web of Science ®Google Scholar
• Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000;23:587–590.
   PubMed Web of Science ®Google Scholar
• Geer MI, Koul PA, Tanki SA, et al. Frequency, types, severity, preventability and costs of adverse drug reactions at a tertiary care hospital. J Pharmacol Toxicol Methods. 2016;81:323–334.
   PubMed Web of Science ®Google Scholar
• Sankar PL, Parker LS. The Precision Medicine Initiative’s all of us research program: an agenda for research on its ethical, legal, and social issues. Genet Med. 2017;19:743–750.
   PubMed Web of Science ®Google Scholar
• Bai JPF, Fontana RJ, Price ND, et al. Systems pharmacology modeling: an approach to improving drug safety. Biopharm Drug Dispos. 2014;35:1–14.
   PubMed Web of Science ®Google Scholar
• Schotland P, Bojunga N, Zien A, et al. Improving drug safety with a systems pharmacology approach. Eur J Pharm Sci. 2016;94:84–92.
   PubMed Web of Science ®Google Scholar
• Trame MN, Biliouris K, Lesko LJ, et al. Systems pharmacology to predict drug safety in drug development. Eur J Pharm Sci. 2016;94:93–95.
   PubMed Web of Science ®Google Scholar
• Korkontzelos I, Nikfarjam A, Shardlow M, et al. Analysis of the effect of sentiment analysis on extracting adverse drug reactions from tweets and forum posts. J Biomed Inform. 2016;62:148–158.
   PubMed Web of Science ®Google Scholar
• White RW, Wang S, Pant A, et al. Early identification of adverse drug reactions from search log data. J Biomed Inform. 2016;59:42–48.
   PubMed Web of Science ®Google Scholar
• Wolverton SE. Practice gaps: drug reactions. Dermatol Clin. 2016;34:311–318.
   PubMed Web of Science ®Google Scholar